{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:31:29Z","timestamp":1785857489000,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07757-3","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:37:09Z","timestamp":1757666229000},"page":"1001-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients"],"prefix":"10.1007","volume":"40","author":[{"given":"Shriya","family":"Chunduri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Bidaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milee","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelmaksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-3787","authenticated-orcid":false,"given":"Jamil","family":"Borgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"Toraih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"14","key":"7757_CR1","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1001\/jama.281.14.1291","volume":"281","author":"K Gu","year":"1999","unstructured":"Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281(14):1291\u20137. https:\/\/doi.org\/10.1001\/jama.281.14.1291.","journal-title":"JAMA"},{"issue":"1","key":"7757_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5853\/jos.2022.02306","volume":"25","author":"O Mosenzon","year":"2023","unstructured":"Mosenzon O, Cheng AY, Rabinstein AA, Sacco S. Diabetes and stroke: what are the connections? J Stroke. 2023;25(1):26\u201338. https:\/\/doi.org\/10.5853\/jos.2022.02306.","journal-title":"J Stroke"},{"issue":"3","key":"7757_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ccl.2014.04.001","volume":"32","author":"D Aronson","year":"2014","unstructured":"Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014;32(3):439\u201355. https:\/\/doi.org\/10.1016\/j.ccl.2014.04.001.","journal-title":"Cardiol Clin"},{"key":"7757_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-981-15-2517-9_3","volume":"1177","author":"D Gu","year":"2020","unstructured":"Gu D, Qu J, Zhang H, Zheng Z. Revascularization for coronary artery disease: principle and challenges. Adv Exp Med Biol. 2020;1177:75\u2013100. https:\/\/doi.org\/10.1007\/978-981-15-2517-9_3.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"7757_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11892-002-0052-z","volume":"2","author":"RL Frye","year":"2002","unstructured":"Frye RL, Bell MR, Schaff HV, Holubkov R, Detre KM. The role of PCI and CABG in the management of coronary artery disease in patients with diabetes. Curr Diab Rep. 2002;2(1):16\u201320. https:\/\/doi.org\/10.1007\/s11892-002-0052-z.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"7757_CR6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2337\/diacare.26.5.1518","volume":"26","author":"FA McAlister","year":"2003","unstructured":"McAlister FA, Man J, Bistritz L, Amad H, Tandon P. Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care. 2003;26(5):1518\u201324. https:\/\/doi.org\/10.2337\/diacare.26.5.1518.","journal-title":"Diabetes Care"},{"issue":"5","key":"7757_CR7","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.ejcts.2009.11.042","volume":"37","author":"AH van Straten","year":"2010","unstructured":"van Straten AH, Soliman Hamad MA, van Zundert AA, et al. Diabetes and survival after coronary artery bypass grafting: comparison with an age- and sex-matched population. Eur J Cardiothorac Surg. 2010;37(5):1068\u201374. https:\/\/doi.org\/10.1016\/j.ejcts.2009.11.042.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"8","key":"7757_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2017.05.005","volume":"36","author":"CA Muir","year":"2017","unstructured":"Muir CA, Greenfield JR, MacDonald PS. Empagliflozin in the management of diabetes mellitus after cardiac transplantationResearch Correspondenceretain\u2013>. J Heart Lung Transplant. 2017;36(8):914\u20136. https:\/\/doi.org\/10.1016\/j.healun.2017.05.005.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"7757_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.healun.2021.02.012","volume":"40","author":"Y Sammour","year":"2021","unstructured":"Sammour Y, Nassif M, Magwire M, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of excellence. J Heart Lung Transplant. 2021;40(6):426\u20139. https:\/\/doi.org\/10.1016\/j.healun.2021.02.012.","journal-title":"J Heart Lung Transplant"},{"issue":"10296","key":"7757_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/s0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376. https:\/\/doi.org\/10.1016\/s0140-6736(21)00536-5.","journal-title":"Lancet"},{"issue":"3","key":"7757_CR11","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.3892\/etm.2020.8714","volume":"20","author":"RA Iorga","year":"2020","unstructured":"Iorga RA, Bacalbasa N, Carsote M, et al. Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Exp Ther Med. 2020;20(3):2396\u2013400. https:\/\/doi.org\/10.3892\/etm.2020.8714.","journal-title":"Exp Ther Med"},{"issue":"19","key":"7757_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"2","key":"7757_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/cd22-0029","volume":"41","author":"P Kushner","year":"2023","unstructured":"Kushner P, Anderson JE, Simon J, et al. Efficacy and safety of tirzepatide in adults with type 2 diabetes: a perspective for primary care providers. Clin Diabetes. 2023;41(2):258\u201372. https:\/\/doi.org\/10.2337\/cd22-0029.","journal-title":"Clin Diabetes"},{"issue":"9","key":"7757_CR14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184(9):1056\u201364. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2525.","journal-title":"JAMA Intern Med"},{"key":"7757_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2907","author":"M Cervantes","year":"2024","unstructured":"Cervantes M, Miles B, Mehta A. Comparison of cardiovascular outcomes in patients with diabetes treated with tirzepatide versus semaglutide: a multi-institutional analysis. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.2907.","journal-title":"Eur Heart J"},{"issue":"2","key":"7757_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/dom.15342","volume":"26","author":"Y Yang","year":"2024","unstructured":"Yang Y, He L, Liu P, et al. Impact of a dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: a systematic review and pairwise and network meta-analysis. Diabetes Obes Metab. 2024;26(2):548\u201356. https:\/\/doi.org\/10.1111\/dom.15342.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"7757_CR17","doi-asserted-by":"publisher","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","volume":"7","author":"M-H Chuang","year":"2024","unstructured":"Chuang M-H, Chen J-Y, Wang H-Y, Jiang Z-H, Wu V-C. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024;7(8):e2427258. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27258.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"7757_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/dom.15318","volume":"26","author":"ER Hankosky","year":"2024","unstructured":"Hankosky ER, Wang H, Neff LM, et al. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024;26(1):319\u201328. https:\/\/doi.org\/10.1111\/dom.15318.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"7757_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"7757_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad026","author":"C Cullinane","year":"2023","unstructured":"Cullinane C, Fullard A, Croghan SM, Elliott JA, Fleming CA. Effect of obesity on perioperative outcomes following gastrointestinal surgery: meta-analysis. BJS Open. 2023. https:\/\/doi.org\/10.1093\/bjsopen\/zrad026.","journal-title":"BJS Open"},{"issue":"2","key":"7757_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/a-2263-1778","volume":"86","author":"A Dincer","year":"2025","unstructured":"Dincer A, Tabor JK, Pappajohn AF, et al. Morbid obesity and diabetes increase the risk of reoperation following microvascular decompression: a national surgical quality improvement program analysis of 1,303 patients. J Neurol Surg B Skull Base. 2025;86(2):234\u201342. https:\/\/doi.org\/10.1055\/a-2263-1778.","journal-title":"J Neurol Surg B Skull Base"},{"key":"7757_CR22","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1016\/j.wneu.2022.03.113","volume":"163","author":"AA Grossen","year":"2022","unstructured":"Grossen AA, Shi HH, O\u2019Neal CM, Bauer AM. Impact of obesity and diabetes on postoperative outcomes following surgical treatment of nontraumatic subarachnoid hemorrhage: analysis of the ACS-NSQIP database. World Neurosurg. 2022;163:e290\u2013300. https:\/\/doi.org\/10.1016\/j.wneu.2022.03.113.","journal-title":"World Neurosurg"},{"key":"7757_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.841256","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Hou A, Cao J, et al. Association of diabetes mellitus with postoperative complications and mortality after non-cardiac surgery: a meta-analysis and systematic review. Front Endocrinol (Lausanne). 2022;13:841256. https:\/\/doi.org\/10.3389\/fendo.2022.841256.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"7757_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01707-4.","journal-title":"Nat Med"},{"issue":"5","key":"7757_CR25","doi-asserted-by":"publisher","first-page":"101740","DOI":"10.1016\/j.jacadv.2025.101740","volume":"4","author":"SS Dani","year":"2025","unstructured":"Dani SS, Makwana B, Khadke S, et al. An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists. JACC Adv. 2025;4(5):101740. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101740.","journal-title":"JACC Adv"},{"key":"7757_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1\u201311. https:\/\/doi.org\/10.1016\/j.ahj.2023.09.007.","journal-title":"Am Heart J"},{"issue":"2","key":"7757_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/fca-2022-0093","volume":"19","author":"AR Watkins","year":"2023","unstructured":"Watkins AR, Fialka N, El-Andari R, et al. Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials. Future Cardiol. 2023;19(2):105\u201315. https:\/\/doi.org\/10.2217\/fca-2022-0093.","journal-title":"Future Cardiol"},{"key":"7757_CR28","doi-asserted-by":"publisher","first-page":"1125126","DOI":"10.3389\/fcvm.2023.1125126","volume":"10","author":"L Harik","year":"2023","unstructured":"Harik L, Perezgrovas-Olaria R, Soletti G Jr, et al. Graft thrombosis after coronary artery bypass surgery and current practice for prevention. Front Cardiovasc Med. 2023;10:1125126. https:\/\/doi.org\/10.3389\/fcvm.2023.1125126.","journal-title":"Front Cardiovasc Med"},{"key":"7757_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2024.104669","volume":"153","author":"E Hosseini","year":"2024","unstructured":"Hosseini E, Ahmadi J, Kargar F, Ghasemzadeh M. Coronary artery bypass grafting (CABG) induces pro-inflammatory and immunomodulatory phenotype of platelets in the absence of a pro-aggregatory state. Microvasc Res. 2024;153:104669. https:\/\/doi.org\/10.1016\/j.mvr.2024.104669.","journal-title":"Microvasc Res"},{"issue":"20","key":"7757_CR30","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.4103\/0366-6999.167372","volume":"128","author":"B Cheng","year":"2015","unstructured":"Cheng B, Mu JS, Zhang JQ, Bo P. Sudden thrombosis in coronary artery bypass grafting surgery. Chin Med J (Engl). 2015;128(20):2835\u20136. https:\/\/doi.org\/10.4103\/0366-6999.167372.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"7757_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1538-7836.2003.00109.x","volume":"1","author":"N Li","year":"2003","unstructured":"Li N, Astudillo R, Ivert T, Hjemdahl P. Biphasic pro-thrombotic and inflammatory responses after coronary artery bypass surgery. J Thromb Haemost. 2003;1(3):470\u20136. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00109.x.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"7757_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/23969873241234238","volume":"9","author":"MI Stefanou","year":"2024","unstructured":"Stefanou MI, Theodorou A, Malhotra K, et al. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis. Eur Stroke J. 2024;9(3):530\u20139. https:\/\/doi.org\/10.1177\/23969873241234238.","journal-title":"Eur Stroke J"},{"issue":"5","key":"7757_CR33","doi-asserted-by":"publisher","first-page":"101740","DOI":"10.1016\/j.jacadv.2025.101740","volume":"4","author":"SS Dani","year":"2025","unstructured":"Dani SS, Makwana B, Khadke S, et al. An observational study of cardiovascular outcomes of Tirzepatide vs glucagon-like peptide-1 receptor agonists. JACC: Advances. 2025;4(5):101740. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101740.","journal-title":"JACC: Advances"},{"issue":"1","key":"7757_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13300-024-01659-7","volume":"16","author":"SC Bain","year":"2025","unstructured":"Bain SC, Belmar N, Hoff ST, et al. Cardiovascular, metabolic, and safety outcomes with semaglutide by baseline age: post hoc analysis of SUSTAIN 6 and PIONEER 6. Diabetes Ther. 2025;16(1):15\u201328. https:\/\/doi.org\/10.1007\/s13300-024-01659-7.","journal-title":"Diabetes Ther"},{"key":"7757_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14796678.2025.2511412","volume":"21","author":"RJ MacIsaac","year":"2025","unstructured":"MacIsaac RJ. Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. Future Cardiol. 2025;21:1. https:\/\/doi.org\/10.1080\/14796678.2025.2511412.","journal-title":"Future Cardiol"},{"issue":"3","key":"7757_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","volume":"34","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Charlton M, Gray M, Noureddin M. The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists. Expert Opin Investig Drugs. 2025;34(3):169\u201395. https:\/\/doi.org\/10.1080\/13543784.2025.2473062.","journal-title":"Expert Opin Investig Drugs"},{"key":"7757_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073832","author":"LG Chrysavgis","year":"2024","unstructured":"Chrysavgis LG, Kazanas S, Bafa K, et al. Glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: novel medication in new liver disease nomenclature. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25073832.","journal-title":"Int J Mol Sci"},{"issue":"Suppl_1","key":"7757_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/circ.146.suppl_1.10370","volume":"146","author":"JA De Lemos","year":"2022","unstructured":"De Lemos JA, le Roux CW, Mao H, et al. Abstract 10370: effects of tirzepatide on 24-hour ambulatory blood pressure and heart rate in adults with obesity - results from the SURMOUNT-1 ambulatory blood pressure monitoring sub-study. Circulation. 2022;146(Suppl_1):A10370-A. https:\/\/doi.org\/10.1161\/circ.146.suppl_1.10370.","journal-title":"Circulation"},{"issue":"3","key":"7757_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","volume":"12","author":"YK Cho","year":"2023","unstructured":"Cho YK, La Lee Y, Jung CH. The cardiovascular effect of Tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. J Lipid Atheroscler. 2023;12(3):213\u201322. https:\/\/doi.org\/10.12997\/jla.2023.12.3.213.","journal-title":"J Lipid Atheroscler"},{"issue":"2","key":"7757_CR40","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025;31(2):544\u201351. https:\/\/doi.org\/10.1038\/s41591-024-03374-z.","journal-title":"Nat Med"},{"key":"7757_CR41","doi-asserted-by":"publisher","unstructured":"Bin Abdul Malik MH, Khan NN, Chowdhari MJ et al. Evaluating the impact of Tirzepatide on clinical outcomes in patients with heart failure. Cureus. 2025;17(4):e82118. https:\/\/doi.org\/10.7759\/cureus.82118.","DOI":"10.7759\/cureus.82118"},{"key":"7757_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00672","volume":"9","author":"J Rowlands","year":"2018","unstructured":"Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne). 2018;9:672. https:\/\/doi.org\/10.3389\/fendo.2018.00672.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07757-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:20Z","timestamp":1778649680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07757-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7757"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07757-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6347985\/v1","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"4 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized de-identified data from the TriNetX global federated health research network, therefore, ethics committee approval and informed consent were waived. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This study used de-identified patient data from TriNetX. As such, individual informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"This study used de-identified patient data from TriNetX. As such, individual consent for publication was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}